Completed PHASE2 INTERVENTIONAL NCT00073125

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

Sponsor: Abbott

Conditions Carcinoma, Renal Cell

Interventions ABT-510/Thrombospondin-1 mimetic

Updated 5 times since 2017 Last updated: Aug 13, 2007 Started: May 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinoma, Renal Cell and is currently completed. Abbott leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Ann Arbor, United States , Boca Raton, United States , Cary, United States , Chicago, United States , Dallas, United States , Fort Worth, United States , Groningen, Netherlands , Houston, United States , Indianapolis, United States and 6 more locations